Immuron Limited reports a robust 34% year-on-year sales increase for Q1 FY26, driven by strong growth in Australia and the USA, while Canadian sales dip seasonally. The company’s marketing efforts and expanding retail presence underpin this momentum.
Immuron Limited reports a robust 49% increase in FY25 global sales of its immune supplement Travelan, driven by strong growth in Australia and North America. The company plans to accelerate its North American market presence in FY26.
Immuron Limited reports a striking 70% quarter-on-quarter increase in Travelan® sales, driven by expanded pharmacy distribution in Australia and North America.